Performance of SARC-F in Regard to Sarcopenia Definitions, Muscle Mass and Functional Measures

Bahat, Gülistan; Yılmaz, Özlem; Kılıç, Cihan; Ören, Meryem Merve; Karan, Mehmet Akif

doi:10.1007/s12603-018-1067-8

Cited by 165 publications

(121 citation statements)

References 28 publications

Supporting

Mentioning

101

Contrasting

Unclassified

Order By: Relevance

“…It was found to have low sensitivity [0.21, 95% confidence interval (CI) 0.13-0.31], but high specificity (0.90, 95% CI 0.83-0.94). A subsequent study using a Turkish sample found similar values [7]. The latter study also found that the SARC-F tool had only a moderate sensitivity for detecting poor performance in the grip strength and chair rise tests, although using different cut points to those now recommended by EWGSOP2.…”

Section: Introductionmentioning

confidence: 64%

The identification of probable sarcopenia in early old age based on the SARC-F tool and clinical suspicion: findings from the 1946 British birth cohort

et al. 2020

View full text Add to dashboard Cite

Key summary pointsAim To describe the prevalence of probable sarcopenia in a sample of older adults and to investigate (1) the SARC-F tool and (2) clinical risk factors in the identification of probable sarcopenia. Findings The prevalence of probable sarcopenia at age 69 was 19%, and a SARC-F score of ≥ 1 had a reasonable balance of sensitivity (65%) and specificity (72%) for probable sarcopenia. Three clinical risk factors were independently associated with probable sarcopenia: polypharmacy, lower body osteoarthritis and physical inactivity. Message Those with any positive responses to the questions in the SARC-F tool, a history of polypharmacy, lower body osteoarthritis or physical inactivity should be prioritised for the assessment of muscle strength. AbstractPurpose The European Working Group on Sarcopenia in Older People 2 (EWGSOP2) consensus definition introduced the concept of probable sarcopenia as a basis on which to begin treatment. Our aims were to describe the prevalence of probable sarcopenia in older adults and to investigate the utility of (1) the SARC-F tool and (2) clinical risk factors for the identification of those likely to have probable sarcopenia. Methods We used data from the 1946 British birth cohort at age 69, with 1686 participants included in the analyses. We used the EWGSOP2 cut points for weak grip strength and slow chair rise time, with the presence of one or both indicating probable sarcopenia. We examined the sensitivity and specificity of the SARC-F tool for probable sarcopenia. We also examined associations between clinical risk factors and probable sarcopenia. Results The prevalence of probable sarcopenia was 19%. A SARC-F score of ≥ 4 had low sensitivity (15%) and high specificity (99%) for probable sarcopenia, whereas a score of ≥ 1 had higher sensitivity (65%) and reasonable specificity (72%). Three clinical risk factors were independently associated with probable sarcopenia: polypharmacy [OR 2.7 (95% CI 1.7,4.2)], lower body osteoarthritis [OR 1.8 (95% CI 1.3, 2.6)] and physical inactivity [OR of 2.1 (95% CI 1.5, 2.8)]. Conclusion We have shown that EWGSOP2 probable sarcopenia is common in community-dwelling adults in early old age. Those with any positive responses to the questions in the SARC-F tool, a history of polypharmacy, lower body osteoarthritis or physical inactivity should be prioritised for the assessment of muscle strength.

show abstract

Section: Introductionmentioning

confidence: 64%

The identification of probable sarcopenia in early old age based on the SARC-F tool and clinical suspicion: findings from the 1946 British birth cohort

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Recognizing the limited time available during a typical visit to a health care professional, the EWGSOP2 also suggested that case finding should be used to identify older persons at risk for sarcopenia. They recommended the use of clinical symptoms usually associated with sarcopenia or the SARC‐F ( Figure ), a questionnaire with five questions, which has high specificity, albeit low sensitivity, to identify persons with sarcopenia . The SARC‐F has been translated into multiple languages.…”

Section: Evolving Definition Of Sarcopeniamentioning

confidence: 99%

“…They recommended the use of clinical symptoms usually associated with sarcopenia or the SARC-F ( Figure 2), a questionnaire with five questions, which has high specificity, albeit low sensitivity, to identify persons with sarcopenia. [16][17][18][19][20] The SARC-F has been translated into multiple languages. The SARC-F is also recommended by the ICFSR for screening.…”

Section: Primary Sarcopenia (Sarcopenia Of Aging)mentioning

confidence: 99%

Sarcopenia: A Time for Action. An SCWD Position Paper

Bauer

Morley

Schols

et al. 2019

J cachexia sarcopenia muscle

496

370

View full text Add to dashboard Cite

The term sarcopenia was introduced in 1988. The original definition was a “muscle loss” of the appendicular muscle mass in the older people as measured by dual energy x‐ray absorptiometry (DXA). In 2010, the definition was altered to be low muscle mass together with low muscle function and this was agreed upon as reported in a number of consensus papers. The Society of Sarcopenia, Cachexia and Wasting Disorders supports the recommendations of more recent consensus conferences, i.e. that rapid screening, such as with the SARC‐F questionnaire, should be utilized with a formal diagnosis being made by measuring grip strength or chair stand together with DXA estimation of appendicular muscle mass (indexed for height2). Assessments of the utility of ultrasound and creatine dilution techniques are ongoing. Use of ultrasound may not be easily reproducible. Primary sarcopenia is aging associated (mediated) loss of muscle mass. Secondary sarcopenia (or disease‐related sarcopenia) has predominantly focused on loss of muscle mass without the emphasis on muscle function. Diseases that can cause muscle wasting (i.e. secondary sarcopenia) include malignant cancer, COPD, heart failure, and renal failure and others. Management of sarcopenia should consist of resistance exercise in combination with a protein intake of 1 to 1.5 g/kg/day. There is insufficient evidence that vitamin D and anabolic steroids are beneficial. These recommendations apply to both primary (age‐related) sarcopenia and secondary (disease related) sarcopenia. Secondary sarcopenia also needs appropriate treatment of the underlying disease. It is important that primary care health professionals become aware of and make the diagnosis of age‐related and disease‐related sarcopenia. It is important to address the risk factors for sarcopenia, particularly low physical activity and sedentary behavior in the general population, using a life‐long approach. There is a need for more clinical research into the appropriate measurement for muscle mass and the management of sarcopenia. Accordingly, this position statement provides recommendations on the management of sarcopenia and how to progress the knowledge and recognition of sarcopenia.

show abstract

“…The SARC-F questionnaire developed by Malmström and Morley, and first published in 2013, appears to be the most popular screening test [4]. A range of studies has found SARC-F to be characterised by low sensitivity but high specificity [5][6][7][8]. It is stressed, though, that high sensitivity is hugely desirable for a screening test, resulting in a good ability to detect individuals who actually have the condition.…”

Section: Introductionmentioning

confidence: 99%

Comparison of four sarcopenia screening questionnaires in community-dwelling older adults from Poland using six sets of international diagnostic criteria of sarcopenia

et al. 2020

View full text Add to dashboard Cite

Introduction There are four screening sarcopenia questionnaires (SARC-F, SARC-CalF, MSRA-5, MSRA-7). To unambiguously determine which of them is the most effective tool in community-dwelling older adults, we performed a diagnostic accuracy study. The aim of the analysis was to assess the diagnostic values of SARC-F, SARC-CalF, MSRA-5, MSRA-7 and compare their psychometric properties against six criterion standards (EWGSOP1, EWG-SOP2, FNIH, AWGS, IWGS, SCWD criteria). Materials and methods We included 100 community-dwelling volunteers aged � 65yrs. The sensitivity/specificity analyses were performed. Receiver operating characteristic (ROC) curves and area under the ROC curves (AUC) were calculated to compare the overall diagnostic accuracy of the four questionnaires. Ideal screening tools should have reasonably high sensitivity and specificity, and an AUC value above 0.7.

show abstract

Performance of SARC-F in Regard to Sarcopenia Definitions, Muscle Mass and Functional Measures

Cited by 165 publications

References 28 publications

The identification of probable sarcopenia in early old age based on the SARC-F tool and clinical suspicion: findings from the 1946 British birth cohort

The identification of probable sarcopenia in early old age based on the SARC-F tool and clinical suspicion: findings from the 1946 British birth cohort

Sarcopenia: A Time for Action. An SCWD Position Paper

Comparison of four sarcopenia screening questionnaires in community-dwelling older adults from Poland using six sets of international diagnostic criteria of sarcopenia

Contact Info

Product

Resources

About